Clinical bottom line
Low-dose naltrexone (LDN) is an emerging off-label treatment for fibromyalgia that may reduce pain and improve quality of life with a favorable safety profile. Evidence from small randomized trials, case reports, and observational studies suggests LDN can alleviate core fibromyalgia symptoms, potentially through modulation of neuroinflammation and central sensitization. However, data remain limited by small sample sizes and short durations, and LDN is not yet included in formal fibromyalgia management guidelines. Primary care clinicians may consider LDN as an adjunctive option for selected patients, especially those refractory to standard therapies, while awaiting more robust evidence (Younger et al., 2009; Beard et al., 2017).
What the evidence shows
Younger et al. (2009) conducted a randomized, double-blind, placebo-controlled crossover trial demonstrating that LDN significantly reduced fibromyalgia pain and overall symptom severity compared to placebo over 8 weeks. Patients reported improvements in fatigue and mood, with minimal adverse effects.
Beard et al. (2017) reviewed evidence on LDN’s efficacy in fibromyalgia and its impact on oral opioid use, concluding that LDN may decrease pain and reduce opioid requirements, although high-quality trials remain scarce.
Humble et al. (2017) reported on LDN use in complex regional pain syndrome and fibromyalgia, noting symptom improvement and tolerability, supporting LDN’s potential role in chronic pain syndromes involving neuroimmune dysregulation.
Metyas et al. (2018) summarized mechanisms by which LDN may modulate microglial activation and inflammatory cytokines, providing a biological rationale for its analgesic effects in fibromyalgia.
Case reports such as Siembida et al. (2022) and Moser et al. (2025) describe individual patients with fibromyalgia and comorbid depression who responded favorably to LDN, suggesting possible benefits beyond pain control.
Caveats and uncertainty
Most clinical trials of LDN in fibromyalgia are small, single-center, and short-term, limiting generalizability.
Optimal dosing regimens and treatment duration are not standardized.
Placebo effects in fibromyalgia trials are substantial, complicating interpretation.
Long-term safety data are limited, though short-term tolerability appears good.
LDN remains off-label for fibromyalgia, and insurance coverage may be variable.
Mechanistic understanding is evolving but not definitive.
How this may change practice
Primary care providers may consider LDN as an adjunctive therapy for fibromyalgia patients inadequately controlled on conventional treatments, particularly when opioid-sparing is desirable.
Shared decision-making is essential, discussing the limited but promising evidence and off-label status.
Monitoring for efficacy and tolerability should guide ongoing use.
LDN could be integrated into multimodal fibromyalgia management plans emphasizing nonpharmacologic and pharmacologic strategies.
Further research participation and awareness of emerging data will inform future guideline updates.